The Venom Kit — a snakebite autoinjector, built from the front

"I ain't no researcher. I'm not gonna make it happen. But logically, how would you go about doing it with the data sources you have available?" — Travis Jenkins, prompt 14 of 15

Read this first This is an educational design exercise, not a clinical protocol. Nothing here should be used for actual medical treatment. The proposal is a starting point for research discussion — a conceptual framework, not a finished product. The honesty about what doesn't exist yet (Part V) is the most important part of the document.

I. The problem — why snakebite treatment hasn't changed

80–140k

deaths per year worldwide (WHO)

$1k–$10k+

per antivenom dose

widely available field treatments

Antivenom has saved millions of lives for over a century — but it needs IV administration in a hospital, a refrigerated cold chain, and is species-specific. It's expensive, can cause serum sickness, and doesn't prevent local tissue damage — people still lose fingers and hands even with it. And it's unavailable in most rural areas where the bites actually happen.

On 31 December 2025, the WHO published Target Product Profiles for next-generation snakebite therapeutics — two modalities, small-molecule drugs and engineered antibody biologics — and explicitly flagged their potential as pre-hospital "first aid" interventions, given before a patient can reach a hospital. That field-deployable, shelf-stable, broad-spectrum, self-administrable niche is the gap this proposal aims at.

II. The three components

Three drugs, three venom pathways, one case the size of an EpiPen.

Component 1 · local injection

Botulinum Toxin Type A (Botox)

Block acetylcholine at the bite site to prevent muscle spasms, tissue necrosis, and the inflammatory cascade.

This is the spark. In a study published in Toxicon (Vol. 270, Feb. 1, 2026), Chinese researchers at Lishui Central Hospital injected pit-viper venom (Deinagkistrodon acutus, the Chinese moccasin) into the thigh muscle of rabbits, then treated some with Botox at the injury site. The results, the right way around: the untreated rabbits' thighs swelled to more than 30% over their original circumference, while the rabbits that also got Botox "barely had any swelling" (Science News). Muscle death fell, inflammatory cytokines dropped, and — crucially — Botox shifted macrophages from inflammatory (M1) to tissue-repair (M2) mode. It didn't just reduce damage; it promoted healing. This proposal imagines it delivered as a lyophilized (freeze-dried) powder in a dual-chamber autoinjector, reconstituted with saline at the moment of use — a design assumption, not a tested formulation.

MED 310 assignmentThe rabbit study used pit-viper venom (D. acutus) — a hemotoxic/myotoxic bite where much of the local damage is metalloproteinase-mediated. Would Botox work as well against primarily neurotoxic venoms (cobras, kraits, mambas)? Analyze the biochemical difference and predict efficacy across venom types.

Component 2 · oral tablet

Unithiol (DMPS)

Chelate the zinc that snake venom metalloproteinases (SVMPs) need to destroy tissue and rupture blood vessels.

A heavy-metal-chelating drug — licensed in Europe (as Dimaval) and available through U.S. compounding pharmacies, though not FDA-approved. SVMPs are zinc-dependent enzymes; unithiol grabs the zinc and shuts them off. An open-label Phase I trial in Kilifi County, Kenya (TRUE-1, 2025) showed it's safe at high oral doses and stable at room temperature. Honest numbers from that trial: blood levels peak at roughly 2–3 hours (not minutes), and the recommended regimen was a 1,500 mg loading dose followed by 900 mg at 6 and 24 hours — not a single small tablet. No refrigeration required.

CHEM 301 assignmentMap the binding kinetics: at what blood concentration does unithiol achieve >90% inhibition of SVMPs? Compare the TRUE-1 Phase I blood levels (Tmax ≈ 2–3 h) to the IC50 of unithiol against common viper SVMPs — and discuss what a 2–3 hour peak means for a treatment meant to be given in the field.

Component 3 · oral capsule

Varespladib

Block phospholipase A2 (PLA2) — the enzyme behind neurotoxicity, membrane destruction, and systemic paralysis.

A PLA2 inhibitor (varespladib) that completed a Phase II snakebite trial (BRAVO, 2024). It's orally bioavailable and broad-spectrum across snake-venom PLA2 enzymes — PLA2 is one of the most common toxic components across species, from elapids (cobras, kraits, coral snakes, mambas) to many vipers. The honest read of the trial: it did not meet its primary endpoint overall, though it was safe and well tolerated and showed a benefit signal in patients treated within five hours of the bite. In BRAVO the dose was a 500 mg loading dose (given as 250 mg tablets), then 250 mg twice daily for seven days — a treatment course, not one capsule.

III. The delivery system & the cost case

The Botox rides in a dual-chamber autoinjector (Windgap-style): dry powder in Chamber 1, saline in Chamber 2. Twist the cap to mix, wait 5–10 seconds for reconstitution, press against the bite, spring-loaded needle deploys. One-handed — critical for solo administration. The full kit fits an EpiPen-sized case, weighs under 200 g, stores at room temperature for 2–3 years.

$75–125

estimated kit cost, mass production

vs $1k–10k+

per antivenom dose + hospital

<200 g

room-temp · 2–3 yr shelf life

The protocol

Twist & inject. Mix the Botox, press the injector against the bite, hold 3 seconds.
Take the unithiol dose immediately. (Proposed field simplification — the tested trial regimen is larger; see Component 2.)
Swallow the varespladib dose. (Trial dosing was a 7-day course; see Component 3.)
Bandage & immobilize. Pressure wrap, still the limb.
Get to a hospital for antivenom if needed. The kit buys time — it may not replace antivenom in severe envenomations.

IV. The coverage — three pathways, one kit

Venom pathway	Component	Mechanism	Snakes covered
Cytotoxic / myotoxic local tissue & muscle death	Botox	Blocks acetylcholine; shifts macrophages M1→M2	Pit vipers (D. acutus — the tested species), rattlesnakes, water moccasins; possibly spitting cobras
Hemotoxic blood-vessel destruction, bleeding	Unithiol	Chelates zinc in SVMPs, deactivating them	Rattlesnakes, copperheads, pit vipers, Russell's viper, puff adder, Gaboon viper
Neurotoxic paralysis, respiratory failure	Varespladib	Blocks PLA2 enzymes	Cobras, kraits, coral snakes, mambas, tiger snakes, taipans

One universal kit beats five regional variants. Venom chemistry crosses borders — a Tennessee rattlesnake and an Indian Russell's viper both run hemotoxic SVMPs; an Alabama coral snake and a Bangladeshi krait both run neurotoxic PLA2. The delivery animal differs; the chemistry is the same. And you don't have to identify the snake before treating — the kit covers the major pathways regardless.

MED 401 assignmentDesign a clinical trial protocol. What Phase I safety questions come first? What endpoints would a Phase II efficacy trial measure? How do you handle a placebo arm ethically when the field control is "no treatment"? Propose an adaptive design that tests all three components individually and in combination.

V. The gaps — what doesn't exist yet

This is the honest asterisk, and it's the part that matters most:

Interaction effects. Nobody has tested Botox + Unithiol + Varespladib together. Different pathways suggest synergy is plausible — but antagonism is also possible. That's the first thing lab testing needs to settle.

Dosing precision. Human bites vary wildly, from dry bites to full envenomations. The kit may need strength variants, or a single max-dose approach on the logic that over-treating a mild bite beats under-treating a severe one.

Species outliers. Sea snakes and some Australian elapids carry venom components outside these three pathways — partial, not complete, coverage.

Regulatory pathway. Botox-for-snakebite is brand new (published early 2026); unithiol and varespladib are in trials but not approved for this indication — and unithiol isn't FDA-approved for anything. Repurposing existing drugs is faster than new-drug development, but still needs Phase I–III. Realistic timeline: prototype in 2–3 years, commercial product in 5–7 if funding and approval align.

VI. How this happened

This wasn't designed by a pharmacologist or a biotech startup. It was designed by a guy reading weird news who saw the Botox-and-snakebite headline and went "oh shit, hell yeah, let me dive off in this direction." Four prompts — about 45 minutes — took it from "huh, that's interesting" to a three-component kit with dosing, delivery design, cost estimates, and a global coverage analysis.

That doesn't make the proposal ready for clinical use. It means the starting point for research — the framework, the component selection, the standardization argument — can emerge from curiosity plus AI collaboration in under an hour. The traditional path produces rigor over years. The Page 14-B path produces the idea the rigor gets applied to. Both have value; they just sit at different ends of the same pipeline.

Companion: the Page 14-B method, made interactive — Browse → Philosophy → Attack, the mechanism behind this kit.

Closing · the Quantum Sandwich was asked for a probability assessment

"Probability of this kit saving lives if funded and tested: 73.2%. Probability of a researcher reading this and recognizing the combination is novel: 94.7%. Probability of funding arriving before the next 80,000 people die from snakebites: insufficient data. Eat your fish sticks. They exist in all probability states."

VII. Sources — every claim above, cited

This page was fact-checked against primary literature. The Page 14-B method produced the idea; the citations are where the rigor gets applied. Six links carry the science:

#	Source	What it backs
1	WHO — Snakebite envenoming	81,000–138,000 deaths/year; the burden case
2	WHO — Target Product Profiles (31 Dec 2025)	The field-treatment gap; small-molecule vs. antibody modalities
3	Xie et al., Toxicon 270 (2026)	The Botox / D. acutus pit-viper rabbit study; M1→M2 shift
4	Science News (13 Jan 2026)	Plain-English confirmation the >30% swelling is the untreated group
5	TRUE-1, eBioMedicine (2025)	Unithiol Phase I: safety, room-temp stability, 2–3 h Tmax, dose
6	BRAVO, BMJ Global Health (2024)	Varespladib Phase II: primary endpoint not met; safety; dosing

Corrections log (July 2026): fixed the Botox study's country, snake, injection site, and the inverted swelling figure; corrected the WHO TPP date and framing; noted DMPS is not FDA-approved and its true peak-time and dose; added that varespladib's Phase II did not meet its primary endpoint; and cited all six sources. The corrected facts make the case stronger — the tested snake was a pit viper, exactly the class the “one universal kit” thesis is built on.